Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting.
A Laura NijstadEvelien de Vos-KerkhofCatherine F Enters-WeijnenMarianne D van de WeteringWim J E TissingMatthijs M TibbenHilde RosingArief LalmohamedAlwin D R HuitemaChristian Michel ZwaanPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
When dexamethasone is given intravenously as a component of triple therapy to prevent CINV in children, we advise to reduce the dexamethasone dose by 30% instead of 50%.